Daxor Corporation
Company & revenue
About Daxor Corporation
Who they are
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms.
Detailed revenue, brand and relationship research has not yet been completed for DXR.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
49
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
76
Strong
Financial Strength
57
Business Quality / Moat
66
Management
100
Growth Quality
100
Risk / Durability
74
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
65
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
66/100
Building Historical Record
Model Score 66/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Asset quality scores strongly
- •Insider activity signal is favorable
No material warning is currently being highlighted from the available summary data.
Company-specific research
Questions worth answering for DXR
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can DXR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can DXR fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is DXR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of DXR's score?
Essential Investment Snapshot
Wall Street Score
49
Opportunity Score
65
Market Cap
$62.0M
P/E Ratio
7.0
EPS
$1.60
52-Week High
$14.76
52-Week Low
$8.56
Beta
0.26
Intrinsic Value
$13.56
Analyst Target
$23.00
Shares Outstanding
5.0M
Total Revenue
$869K
Total Debt
$112K
Dividend
No current dividend
Liquidation Value / Share
$10.40
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on DXR.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 19.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
- −Negative free cash flow may increase the need for outside financing and dilution.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
49
Sep 21, 2026
Change
+0.1
points
Current Score
49
Oct 1, 2026
Category Changes
DXR increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
50
Projected Change
+1.4%
Preliminary comparable-period financial changes suggest improvement of approximately 1.4 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$10.62
Intrinsic Value
$13.56
Difference
−$2.94
-21.7% vs IV
Margin of Safety
21.7%
Related Companies
Medical - Instruments & SuppliesNews
Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial